Neurocrine Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>NB</div>
NBIX -- USA Stock  

USD 97.70  1.16  1.17%

It appears Neurocrine Biosciences may not recover as fast as we have hopped for as its price went down 1.12% today. This firm's current daily volatility is 2.61 percent, with a beta of -0.16 and an alpha of 0.32 over DOW. As many millenniums are excited about the current volatility, it is fair to break down Neurocrine Biosciences based on its historical price patterns. We will evaluate why we are still optimistic in anticipation of a recovery.
Published over a month ago
View all stories for Neurocrine Biosciences | View All Stories
Is Neurocrine Biosciences (NASDAQ:NBIX) a new disruptor?
Neurocrine Biosciences currently holds roughly 771.7 M in cash with 302.75 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.31. On a scale of 0 to 100, Neurocrine Biosciences holds a performance score of 8. The company secures a Beta (Market Risk) of -0.1591, which conveys not very significant fluctuations relative to the market. Let's try to break down what Neurocrine's beta means in this case. As returns on the market increase, returns on owning Neurocrine Biosciences are expected to decrease at a much lower rate. During the bear market, Neurocrine Biosciences is likely to outperform the market. Although it is vital to follow Neurocrine Biosciences price patterns, it is good to be conservative about what you can do with the information regarding equity historical price patterns. The philosophy towards estimating future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Neurocrine Biosciences technical indicators, you can presently evaluate if the expected return of 0.33% will be sustainable into the future. Please exercises Neurocrine Biosciences jensen alpha and semi variance to make a quick decision on whether Neurocrine Biosciences current price movements will revert.
Investing in Neurocrine Biosciences, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Neurocrine Biosciences along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.

How important is Neurocrine Biosciences's Liquidity

Neurocrine Biosciences financial leverage refers to using borrowed capital as a funding source to finance Neurocrine Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Neurocrine Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Neurocrine Biosciences's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Neurocrine Biosciences, but it might be worth checking our own buy vs. sell analysis

Neurocrine Biosciences Correlation with Peers

Investors in Neurocrine can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Neurocrine Biosciences. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Neurocrine Biosciences and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Neurocrine is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Neurocrine for more details

Sale by Julie Cooke of 2257 shares of Neurocrine Biosciences

Legal trades by Neurocrine Biosciences insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Neurocrine insider trading alert for sale of common stock by Julie Cooke, Chief Human Resources Officer, on 7th of August 2020. This event was filed by Neurocrine Biosciences In with SEC on 2020-08-07. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper look at Neurocrine

Neurocrine Biosciences appears to be very steady, given 1 month investment horizon. Neurocrine Biosciences has Sharpe Ratio of 0.13, which conveys that the firm had 0.13% of return per unit of risk over the last month. Our standpoint towards estimating the volatility of a stock is to use all available market data together with stock specific technical indicators that cannot be diversified away. We have found twenty-one technical indicators for Neurocrine Biosciences, which you can use to evaluate future volatility of the firm. Please exercise Neurocrine Biosciences Downside Deviation of 2.5, mean deviation of 2.15, and Risk Adjusted Performance of 0.1883 to check out if our risk estimates are consistent with your expectations.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Analysis of Neurocrine Biosciences

Current Information Ratio is up to 0.05. Price may slide again. As of the 2nd of August, Neurocrine Biosciences secures the Downside Deviation of 2.5, mean deviation of 2.15, and Risk Adjusted Performance of 0.1883. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neurocrine Biosciences, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to break down and interpolate data for nineteen technical drivers for Neurocrine Biosciences, which can be compared to its peers in the industry. Please verify Neurocrine Biosciences jensen alpha and semi variance to decide if Neurocrine Biosciences is priced some-what accurately, providing market reflects its recent price of 120.36 per share. Given that Neurocrine Biosciences has jensen alpha of 0.3191, we recommend you to check Neurocrine Biosciences's last-minute market performance to make sure the company can sustain itself at a future point.

Our Bottom Line On Neurocrine Biosciences

While other entities in the biotechnology industry are either recovering or due for a correction, Neurocrine may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Neurocrine valuation and our trade advice on Neurocrine Biosciences is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Neurocrine Biosciences.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Neurocrine Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com